Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-09-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
江苏泰和律师事务所关于金陵药业股份有限公司2024年第三次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality and validity of the 2024 third extraordinary general meeting of shareholders of Jinling Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or management discussion but focuses on the legality and procedural aspects of the shareholders' meeting and its resolutions. It is not a full annual or interim report, nor an earnings release or management report. It is not a proxy solicitation or voting results announcement per se, but a legal opinion on the meeting. Given the nature and content, this fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes legal opinions related to corporate governance events.
2024-09-13 Chinese
金陵药业股份有限公司关于回购注销部分限制性股票减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Jinling Pharmaceutical Co., Ltd. regarding the repurchase and cancellation of part of its restricted shares, which leads to a reduction in registered capital. It includes detailed information about the board and supervisory meetings approving the repurchase, the legal basis for notifying creditors, and instructions for creditors to claim debts or request guarantees. The document is a formal public notice about a capital change event, specifically a share repurchase and cancellation that affects the company's registered capital. It is not a financial report, earnings release, or management discussion, nor is it a voting result or AGM material. The content fits the definition of a Share Issue/Capital Change announcement, as it concerns changes in share capital due to repurchase and cancellation of shares.
2024-09-13 Chinese
金陵药业股份有限公司关于召开2024年第三次临时股东大会的提示性公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement about the convening of the 2024 third extraordinary general meeting of shareholders for Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on, registration methods, and proxy forms. There is no financial data, earnings information, or management discussion of financial results. The document is not a report itself but an announcement and instructions related to a shareholder meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than the solicitation materials or proxy statement, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA) because it relates to voting rights and meeting details. The document length is under 5,000 characters, but it is detailed and not just a brief report publication announcement. Therefore, the best fit is DVA.
2024-09-10 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the use of idle raised funds for cash management by Jinling Pharmaceutical Co., Ltd. It details the amounts, dates, expected yields, and risk control measures related to the cash management of idle raised funds. The document references prior approvals by the board and shareholders and provides updates on the current status and risk controls. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is a specific update on capital usage and cash management activities, which aligns with Capital/Financing Update filings. The document length is about 4552 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-09-10 Chinese
金陵药业股份有限公司关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of using idle raised funds for cash management. It details the amounts invested, types of financial products, expected yields, risk control measures, and the impact on company operations. The document is relatively short (4390 characters) and focuses on reporting the progress and status of cash management activities rather than providing comprehensive financial statements or detailed financial analysis. It does not contain full financial results or detailed management discussion. It is an update on financing/capital management activities related to the use of raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-09-04 Chinese
金陵药业股份有限公司关于2024年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a special report on the storage and usage of funds raised in the first half of 2024 by Jinling Pharmaceutical Co., Ltd. It details the amount of funds raised through a specific stock issuance, the net proceeds, the usage and balance of these funds, and compliance with regulatory requirements. It includes detailed tables on the funds' allocation, usage, and cash management activities. The document references regulatory approvals and audit reports related to the fundraising but does not present comprehensive financial statements or overall company performance data. The content focuses specifically on the capital raised and its management, which aligns with updates on company fundraising and capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-08-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.